---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-015621"
form_type: "8-K"
ticker: "PBYI"
cik: "0001401667"
company_name: "PUMA BIOTECHNOLOGY, INC."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:32:47.181763+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Puma Biotech Q1 net loss $3.8M; raises 2026 revenue and net income guidance on NERLYNX demand

## Summary
- Q1 product revenue $42.0M vs $43.1M YoY; GAAP net loss $3.8M ($0.07/share) vs net income $3.0M.
- Non-GAAP adjusted net loss $1.9M ($0.04/share) vs adjusted net income $5.0M ($0.10) YoY.
- FY 2026 guidance raised: net product revenue $202-206M (prior $194-198M); net income $16-19M (prior $10-13M).
- Debt fully repaid on May 4, 2026; cash & securities $101.5M at March 31, 2026, up from $97.5M.
- Second-quarter Q2 2026 net product revenue guidance $50-52M, net income $2-4M.

## SEC filing metadata
- accession: 0001437749-26-015621
- form_type: 8-K
- ticker: PBYI
- cik: 0001401667
- company_name: PUMA BIOTECHNOLOGY, INC.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401667/000143774926015621/0001437749-26-015621-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401667/000143774926015621/pbyi20260327_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-015621
- JSON: https://secwatch.observer/filing/0001437749-26-015621.json
- Plain text: https://secwatch.observer/filing/0001437749-26-015621.txt

## Source-grounded claims
- claim_id: 6066f2c1e55088d3c239ce5909a337b76ea8b8d0
  claim: PUMA BIOTECHNOLOGY, INC. reported first quarter ended March 31, 2026 results: revenue $44.8 million, net income net loss of $3.8 million, EPS $0.07 per basic and diluted share. Guidance raised.
  evidence_excerpt: consists of product revenue, net from sales of NERLYNX, Puma’s first commercial product, and royalty revenue. For the first quarter ended March 31, 2026 , total revenue was $44.8 million, of which $42.0 million was net product revenue and $2.8 million was royalty revenue. This compares to total revenue of $46.0 million in the first quarter of 2025 , of which
  evidence_url: https://www.sec.gov/Archives/edgar/data/1401667/000143774926015621/0001437749-26-015621-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.